CXCL10 and myeloid sarcoma: IP10 levels were also higher in the progressive forms of MS (SP-MS and PP-MS) than in the rest of RR-MS patients without treatment studied: In PP-MS patients, there was a modest increase (96±75 vs 75±78, p = 0.05), whereas in SP-MS patients these differences were more remarkable (102±52 vs 75±78, p = 0.0001).